Is VTv Therapeutics Stock a Good Investment?
VTv Therapeutics Investment Advice | VTVT |
- Examine VTv Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research VTv Therapeutics' leadership team and their track record. Good management can help VTv Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact VTv Therapeutics' business and its evolving consumer preferences.
- Compare VTv Therapeutics' performance and market position to its competitors. Analyze how VTv Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if VTv Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about VTv Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in vTv Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if vTv Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Modest | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine VTv Therapeutics Stock
Researching VTv Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 39.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 4.37. vTv Therapeutics had not issued any dividends in recent years. The entity had 1:40 split on the 21st of November 2023.
To determine if VTv Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding VTv Therapeutics' research are outlined below:
| vTv Therapeutics is way too risky over 90 days horizon | |
| vTv Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 1.02 M. Net Loss for the year was (22.7 M) with loss before overhead, payroll, taxes, and interest of (9.93 M). | |
| vTv Therapeutics currently holds about 17.95 M in cash with (25.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| vTv Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 39.0% of the company outstanding shares are owned by insiders | |
| Latest headline from zacks.com: The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics |
VTv Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in vTv Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to VTv Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact VTv Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises VTv Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-10 | 2022-09-30 | -0.04 | -0.05 | -0.01 | 25 | ||
2020-05-07 | 2020-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2022-05-12 | 2022-03-31 | -0.08 | -0.1 | -0.02 | 25 | ||
2021-05-05 | 2021-03-31 | -0.06 | -0.08 | -0.02 | 33 | ||
2020-08-03 | 2020-06-30 | -0.09 | -0.07 | 0.02 | 22 | ||
2019-10-30 | 2019-09-30 | -0.11 | -0.13 | -0.02 | 18 | ||
2023-05-11 | 2023-03-31 | -0.09 | -0.06 | 0.03 | 33 | ||
2022-03-29 | 2021-12-31 | -0.07 | -0.11 | -0.04 | 57 |
VTv Therapeutics Target Price Consensus
VTv target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. VTv Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most VTv analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand VTv stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of vTv Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVTv Therapeutics Target Price Projection
VTv Therapeutics' current and average target prices are 16.64 and 35.00, respectively. The current price of VTv Therapeutics is the price at which vTv Therapeutics is currently trading. On the other hand, VTv Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
VTv Therapeutics Market Quote on 23rd of March 2025
Target Price
Analyst Consensus On VTv Therapeutics Target Price
VTv Therapeutics Analyst Ratings
VTv Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about VTv Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of VTv Therapeutics' financials, market performance, and future outlook by experienced professionals. VTv Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know VTv Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as VTv Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading vTv Therapeutics backward and forwards among themselves. VTv Therapeutics' institutional investor refers to the entity that pools money to purchase VTv Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2024-12-31 | 178 | Activest Wealth Management | 2024-12-31 | 50.0 | Parallel Advisors, Llc | 2024-12-31 | 38.0 | Cornerstone Planning Group Llc | 2024-12-31 | 19.0 | Sunbelt Securities | 2024-12-31 | 15.0 | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 9.0 | Bank Of America Corp | 2024-12-31 | 8.0 | Tower Research Capital Llc | 2024-12-31 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Samsara Biocapital, Llc | 2024-12-31 | 206.8 K | Fmr Inc | 2024-12-31 | 178.2 K |
VTv Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.87 M.Market Cap |
|
VTv Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.73) | (0.77) | |
| Return On Assets | (0.48) | (0.51) | |
| Return On Equity | (1.51) | (1.44) |
Determining VTv Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if VTv Therapeutics is a good buy. For example, gross profit margin measures VTv Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of VTv Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in VTv Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of vTv Therapeutics. Check VTv Therapeutics' Beneish M Score to see the likelihood of VTv Therapeutics' management manipulating its earnings.
Evaluate VTv Therapeutics' management efficiency
vTv Therapeutics has return on total asset (ROA) of (0.4148) % which means that it has lost $0.4148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6213) %, meaning that it created substantial loss on money invested by shareholders. VTv Therapeutics' management efficiency ratios could be used to measure how well VTv Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2025. Return On Capital Employed is likely to drop to -0.77 in 2025. Non Current Liabilities Other is likely to gain to about 23.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 4.9 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.48 | 2.60 | |
| Tangible Book Value Per Share | 2.48 | 2.60 | |
| Enterprise Value Over EBITDA | (1.92) | (2.01) | |
| Price Book Value Ratio | 6.53 | 6.86 | |
| Enterprise Value Multiple | (1.92) | (2.01) | |
| Price Fair Value | 6.53 | 6.86 | |
| Enterprise Value | 43.1 M | 61.3 M |
The leadership approach at VTv Therapeutics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 0.629 |
Basic technical analysis of VTv Stock
As of the 23rd of March, VTv Therapeutics has the Risk Adjusted Performance of 0.0557, semi deviation of 4.09, and Coefficient Of Variation of 1897.63. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of vTv Therapeutics, as well as the relationship between them.VTv Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific VTv Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on VTv Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases VTv Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
VTv Therapeutics' Outstanding Corporate Bonds
VTv Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. vTv Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most VTv bonds can be classified according to their maturity, which is the date when vTv Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Viking Cruises Ltd Corp BondUS91832VAA26 | View | |
| US91835HAA05 Corp BondUS91835HAA05 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand VTv Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing VTv Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0557 | |||
| Market Risk Adjusted Performance | 0.2079 | |||
| Mean Deviation | 4.57 | |||
| Semi Deviation | 4.09 | |||
| Downside Deviation | 4.59 | |||
| Coefficient Of Variation | 1897.63 | |||
| Standard Deviation | 8.25 | |||
| Variance | 68.08 | |||
| Information Ratio | 0.0596 | |||
| Jensen Alpha | 0.5694 | |||
| Total Risk Alpha | 1.05 | |||
| Sortino Ratio | 0.1073 | |||
| Treynor Ratio | 0.1979 | |||
| Maximum Drawdown | 66.14 | |||
| Value At Risk | (7.70) | |||
| Potential Upside | 8.18 | |||
| Downside Variance | 21.03 | |||
| Semi Variance | 16.77 | |||
| Expected Short fall | (6.98) | |||
| Skewness | 4.17 | |||
| Kurtosis | 25.59 |
| Risk Adjusted Performance | 0.0557 | |||
| Market Risk Adjusted Performance | 0.2079 | |||
| Mean Deviation | 4.57 | |||
| Semi Deviation | 4.09 | |||
| Downside Deviation | 4.59 | |||
| Coefficient Of Variation | 1897.63 | |||
| Standard Deviation | 8.25 | |||
| Variance | 68.08 | |||
| Information Ratio | 0.0596 | |||
| Jensen Alpha | 0.5694 | |||
| Total Risk Alpha | 1.05 | |||
| Sortino Ratio | 0.1073 | |||
| Treynor Ratio | 0.1979 | |||
| Maximum Drawdown | 66.14 | |||
| Value At Risk | (7.70) | |||
| Potential Upside | 8.18 | |||
| Downside Variance | 21.03 | |||
| Semi Variance | 16.77 | |||
| Expected Short fall | (6.98) | |||
| Skewness | 4.17 | |||
| Kurtosis | 25.59 |
Consider VTv Therapeutics' intraday indicators
VTv Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of VTv Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
VTv Therapeutics Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 23rd of September 2024 Other Reports | ViewVerify |
VTv Stock media impact
Far too much social signal, news, headlines, and media speculation about VTv Therapeutics that are available to investors today. That information is available publicly through VTv media outlets and privately through word of mouth or via VTv internal channels. However, regardless of the origin, that massive amount of VTv data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of VTv Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of VTv Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to VTv Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive VTv Therapeutics alpha.
VTv Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards VTv Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
VTv Therapeutics Corporate Management
| David III | Sr Counsel | Profile | |
| Vanessa McDade | Chief Officer | Profile | |
| Elizabeth Keiley | Executive Counsel | Profile | |
| Carmen Valcarce | Chief VP | Profile | |
| MD FACC | Executive Chairperson | Profile |
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.